QQ客服 官方微博 反馈留言

浏览/检索结果: 共12条，第1-10条 帮助 限定条件 专题：中国医学科学院 北京协和医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Protocol of the China ST-segment elevation myocardial infarction (STEMI) Care Project (CSCAP): a 10-year project to improve quality of care by building up a regional STEMI care network 期刊论文 2019, 卷号: 9, 期号: 7, 页码: e026362 作者:  Zhang Yan;  Yu Bo;  Han Yaling;  Wang Jianan;  Yang Lixia 收藏  |  浏览/下载：32/0  |  提交时间：2020/01/03 ST-elevation myocardial infarction  accreditation  chest pain center  network  reperfusion   A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study 期刊论文 2019, 卷号: 93, 期号: 7, 页码: 1194-1204 作者:  Chen, Yundai;  Yin, Tong;  Xi, Shaozhi;  Zhang, Shuyang;  Yan, Hongbing 收藏  |  浏览/下载：51/0  |  提交时间：2020/01/03 antiplatelet therapy  bleeding  coronary artery disease  percutaneous coronary intervention   Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation A Report From the GARFIELD-AF Registry 期刊论文 2019, 卷号: 4, 期号: 6, 页码: 526-548 作者:  Corbalan, Ramon;  Bassand, Jean-Pierre;  Illingworth, Laura;  Ambrosio, Giuseppe;  Camm, A. John 收藏  |  浏览/下载：72/0  |  提交时间：2020/01/03 Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial 期刊论文 2019, 卷号: 24, 期号: 8, 页码: E702-E708 作者:  Zhou, Ai-Ping;  Bai, Yuxian;  Song, Yan;  Luo, Hong;  Ren, Xiu-Bao 收藏  |  浏览/下载：18/0  |  提交时间：2020/01/03 Anlotinib  Metastatic renal cell cancer  Phase II clinical trial   Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial 期刊论文 2019, 卷号: 4, 期号: 3, 页码: 273-286 作者:  Hochman, Judith S.;  Reynolds, Harmony R.;  Bangalore, Sripal;  O'Brien, Sean M.;  Alexander, Karen P. 收藏  |  浏览/下载：57/0  |  提交时间：2020/01/03 Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial. 期刊论文 2016, 卷号: 34, 期号: 15 作者:  Zhou, Ai-Ping;  Bai, Yuxian;  Song, Van;  Li, Hangzhong;  Xie, Xiaodong 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04 Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial 期刊论文 2016, 卷号: 34, 期号: 15 作者:  Zhou, Ai-Ping;  Ma, Jianhui;  Bai, Yuxian;  Song, Yan;  Li, Hangzhong 收藏  |  浏览/下载：12/0  |  提交时间：2020/01/04 RNF122 suppresses antiviral type I interferon production by targeting RIG-I CARDs to mediate RIG-I degradation 期刊论文 2016, 卷号: 113, 期号: 34, 页码: 9581-9586 作者:  Wang, Wendie;  Jiang, Minghong;  Liu, Shuo;  Zhang, Shikun;  Liu, Wei 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04 RIG-I  E3 ligase  RNF122  innate immunity  type I interferon   Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20 作者:  Zhou, Ai-Ping;  Ma, Jianhui;  Bai, Yuxian;  Song, Yan;  Li, Hangzhong 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/04 Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial. 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20 作者:  Zhou, Ai-Ping;  Bai, Yuxian;  Song, Van;  Li, Hangzhong;  Xie, Xiaodong 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04